Use of the lung cancer-specific Quality of Life Questionnaire EORTC QLQ-LC13 in clinical trials: A systematic review of the literature 20 years after its development

Cancer

Volumn 121, Issue 24, 2015, Pages 4300-4323

  Koller, Michael ^a   Warncke, Sophie ^a   Hjermstad, Marianne J ^b   Arraras, Juan ^c   Pompili, Cecilia ^d   Harle, Amelie ^e   Johnson, Colin D ^f   Chie, Wei Chu ^g   Schulz, Christian ^a   Zeman, Florian ^a   Van Meerbeeck, Jan P ^h   Kulis̈, Dagmara ⁱ   Bottomley, Andrew ⁱ  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c Instituto de Investigación Sanitaria de Navarra   (Spain)

^d ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^e CHRISTIE HOSPITAL   (United Kingdom)

^f UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^g NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^h ANTWERP UNIVERSITY HOSPITAL   (Belgium)

ⁱ EORTC DATA CENTER   (Belgium)

Author keywords

clinical trials; lung cancer; outcome; quality of life

Indexed keywords

AFATINIB; AMIFOSTINE; ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; CISPLATIN; CRIZOTINIB; CYCLOPHOSPHAMIDE; DACOMITINIB; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; HYDRAZINE SULFATE; IFOSFAMIDE; IRINOTECAN; MITOMYCIN; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM COMPLEX; SRL 172; TENIPOSIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CHINESE MEDICINE; CODING AND CLASSIFICATION; DATA BASE; EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE QUESTIONNAIRE LUNG CANCER 13; HUMAN; LUNG CANCER; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLICATION; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREND STUDY; CLINICAL TRIAL (TOPIC); LUNG TUMOR; QUALITY OF LIFE; QUESTIONNAIRE; UTILIZATION;

CLINICAL TRIALS AS TOPIC; HUMANS; LUNG NEOPLASMS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVEYS AND QUESTIONNAIRES;

EID: 84949317284     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29682     Document Type: Article

References (263)

1. Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M,. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer. 1994; 30A: 635-642.
2. Aaronson NK, Ahmedzai S, Bergman B, et al., The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85: 365-376.
3. Salvo N, Hadi S, Napolskikh J, Goh P, Sinclair E, Chow E,. Quality of life measurement in cancer patients receiving palliative radiotherapy for symptomatic lung cancer: a literature review. Curr Oncol. 2009; 16: 16-28.
4. International Consortium for Health Outcomes Measurement (ICHOM). ICHOM Web site. Available at: http://www.ichom.org/. Accessed February 27, 2015.
5. Johnson C, Aaronson N, Blazeby JM, et al., Guidelines for Developing Questionnaire Modules. 4th ed. Brussels, Belgium: European Organization for Research and Treatment of Cancer; 2011.
6. Dewolf L, Koller M, Velikova G, Johnson C, Scott N, Bottomley A,; on behalf of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Group. EORTC Quality of Life Group Translation Procedure. Translation Manual. 3rd ed. Brussels, Belgium: EORTC; 2009.
7. Mapi Research Trust. PROQOLID Web site. Available at: http://www.proqolid.org/. Accessed February 27, 2015.
8. Fallowfield LJ, Harper P,. Health-related quality of life in patients undergoing drug therapy for advanced non-small-cell lung cancer. Lung Cancer. 2005; 48: 365-377.
9. Claassens L, van Meerbeeck J, Coens C, et al., Health-related quality of life in non-small-cell lung cancer: an update of a systematic review on methodologic issues in randomized controlled trials. J Clin Oncol. 2011; 29: 2104-2120.
10. Saad ED, Adamowicz K, Katz A, Jassem J,. Assessment of quality of life in advanced non-small-cell lung cancer: an overview of recent randomized trials. Cancer Treat Rev. 2012; 38: 807-814.
11. Brunelli A, Pompili C, Koller M,. Changes in quality of life after pulmonary resection. Thorac Surg Clin. 2012; 22: 471-485.
12. Damm K, Roeske N, Jacob C,. Health-related quality of life questionnaires in lung cancer trials: a systematic literature review [serial online]. Health Econ Rev. 2013; 3: 15.
13. Camps C, del Pozo N, Blasco A, Blasco P, Sirera R,. Importance of quality of life in patients with non-small-cell lung cancer. Clin Lung Cancer. 2009; 10: 83-90.
14. Montazeri A, Gillis CR, McEwen J,. Quality of life in patients with lung cancer: a review of literature from 1970 to 1995. Chest. 1998; 113: 467-481.
15. Earle CC,. Outcomes research in lung cancer. J Natl Cancer Inst Monogr. 2004; 33: 56-77.
16. Tanvetyanon T, Soares HP, Djulbegovic B, Jacobsen PB, Bepler G,. A systematic review of quality of life associated with standard chemotherapy regimens for advanced non-small cell lung cancer. J Thorac Oncol. 2007; 2: 1091-1097.
17. Efficace F, Bottomley A, Osoba D, et al., Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials-does HRQOL evaluation in prostate cancer research inform clinical decision making? J Clin Oncol. 2003; 21: 3502-3511.
18. Efficace F, Bottomley A, Vanvoorden V, Blazeby JM,. Methodological issues in assessing health-related quality of life of colorectal cancer patients in randomised controlled trials. Eur J Cancer. 2004; 40: 187-197.
19. Bottomley A, Efficace F, Thomas R, Vanvoorden V, Ahmedzai SH,. Health-related quality of life in non-small-cell lung cancer: methodologic issues in randomized controlled trials. J Clin Oncol. 2003; 21: 2982-2992.
20. Abdelaziz M, Bradley A, Agostini P, et al., A multidisciplinary complex perioperative intervention to reduce complications and enhance recovery after lung resection surgery [abstract]. Lung Cancer. 2011; 71 (suppl 1): S26.
21. Amjadi K, Voduc N, Cruysberghs Y, et al., Impact of interventional bronchoscopy on quality of life in malignant airway obstruction. Respiration. 2008; 76: 421-428.
22. Andersen AH, Vinther A, Poulsen L, Mellemgaard A,. Do patients with lung cancer benefit from physical exercise? Acta Oncol. 2011; 50: 307-313.
23. Anderson H, Hopwood P, Stephens RJ, et al., Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer-a randomized trial with quality of life as the primary outcome. Br J Cancer. 2000; 83: 447-453.
24. Arbane G, Tropman D, Jackson D, Garrod R,. Evaluation of an early exercise intervention after thoracotomy for non-small cell lung cancer (NSCLC), effects on quality of life, muscle strength and exercise tolerance: randomised controlled trial. Lung Cancer. 2011; 71: 229-234.
25. Arnold AM, Seymour L, Smylie M, et al., Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol. 2007; 25: 4278-4284.
26. Arrarás JI, Arias de la Vega F, Illarramendi JJ, et al., Health-related quality of life in the oncology departments of the Hospital of Navarra. The EORTC Quality of Life Group [article in Spanish]. An Sist Sanit Navar. 2011; 34: 9-20.
27. Arraras Urdaniz JI, Martinez Aguillo M, Manterola Burgaleta A, et al., Quality of life assessment in Spanish lung cancer patients by the EORTC questionnaires. Oncología. 2005; 28: 174-182.
28. Arrieta Ó, Angulo LP, Núñez-Valencia C, et al., Association of depression and anxiety on quality of life, treatment adherence, and prognosis in patients with advanced non-small cell lung cancer. Ann Surg Oncol. 2013; 20: 1941-1948.
29. Arrieta Ó, Núñez-Valencia C, Reynoso-Erazo L, et al., Health-related quality of life in patients with lung cancer: validation of the Mexican-Spanish version and association with prognosis of the EORTC QLQ-LC13 questionnaire. Lung Cancer. 2012; 77: 205-211.
30. Bagust A, Barraza-Llorens M, Philips Z,. Deriving a compound quality of life measure from the EORTC-QLQ-C30/LC13 instrument for use in economic evaluations of lung cancer clinical trials. Eur J Cancer. 2001; 37: 1081-1088.
31. Baka S, Ashcroft L, Anderson H, et al., Randomized phase II study of 2 gemcitabine schedules for patients with impaired performance status (Karnofsky performance status ≤ 70) and advanced non-small cell lung cancer. J Clin Oncol. 2005; 23: 2136-2144.
32. Balduyck B, Hendriks J, Lauwers P, van Schil P,. Quality of life evolution after lung cancer surgery: a prospective study in 100 patients. Lung Cancer. 2007; 56: 423-431.
33. Balduyck B, Hendriks J, Lauwers P, Van Schil P,. Quality of life evolution after surgery for primary or secondary spontaneous pneumothorax: a prospective study comparing different surgical techniques. Interact Cardiovasc Thorac Surg. 2008; 7: 45-49.
34. Balduyck B, Hendriks J, Lauwers P, Nia PS, Van Schil P,. Quality of life evolution after lung cancer surgery in septuagenarians: a prospective study. Eur J Cardiothorac Surg. 2009; 35: 1070-1075.
35. Balduyck B, Hendriks J, Lauwers P, Van Schil P,. Quality of life after lung cancer surgery: a prospective pilot study comparing bronchial sleeve lobectomy with pneumonectomy. J Thorac Oncol. 2008; 3: 604-608.
36. Balduyck B, Hendriks JM, Lauwers P, Mercelis R, Ten Broecke P, Van Schil P,. Quality of life after anterior mediastinal mass resection: a prospective study comparing open with robotic-assisted thoracoscopic resection. Eur J Cardiothorac Surg. 2011; 39: 543-548.
37. Balduyck B, Sardari Nia P, Cogen A, et al., The effect of smoking cessation on quality of life after lung cancer surgery. Eur J Cardiothorac Surg. 2011; 40: 1432-1438.
38. Balduyck B, van Thielen J, Cogen A, et al., Quality of life evolution after pulmonary metastasectomy: a prospective study comparing isolated lung perfusion with standard metastasectomy. J Thorac Oncol. 2012; 7: 1567-1573.
39. Barlesi F, Doddoli C, Loundou A, Pillet E, Thomas P, Auquier P,. Preoperative psychological global well being index (PGWBI) predicts postoperative quality of life for patients with non-small cell lung cancer managed with thoracic surgery. Eur J Cardiothorac Surg. 2006; 30: 548-553.
40. Barlési F, Barrau K, Doddoli C, et al., Phase III randomised trial of adjuvant chemotherapy with cisplatin plus docetaxel versus cisplatin plus gemcitabine in resected non-small cell bronchial carcinoma with quality of live as primary objective [article in French]. Rev Mal Respir. 2006; 23 (5 pt 1): 489-498.
41. Bar-Sela G, Wollner M, Hammer L, Agbarya A, Dudnik E, Haim N,. Mistletoe as complementary treatment in patients with advanced non-small-cell lung cancer treated with carboplatin-based combinations: a randomised phase II study. Eur J Cancer. 2013; 49: 1058-1064.
42. Baysungur V,. Quality of life assessment 6 months after lobectomy for lung cancer: video-assisted thoracoscopic surgery versus thoracotomy. Turk J Thorac Cardiovasc Surg. 2011; 19: 207-212.
43. Berendes D, Keefe FJ, Somers TJ, Kothadia SM, Porter LS, Cheavens JS,. Hope in the context of lung cancer: relationships of hope to symptoms and psychological distress. J Pain Symptom Manage. 2010; 40: 174-182.
44. Bezjak A, Tu D, Seymour L, et al., Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 2006; 24: 3831-3837.
45. Bianco V, Di Girolamo B, Pignatelli E, et al., Gemcitabine as single agent therapy in advanced nonsmall cell lung cancer and quality of life in the elderly. Panminerva Med. 2001; 43: 15-19.
46. Booth S, Adams L,. The shuttle walking test: a reproducible method for evaluating the impact of shortness of breath on functional capacity in patients with advanced cancer. Thorax. 2001; 56: 146-150.
47. Booton R, Lorigan P, Anderson H, et al., A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). Ann Oncol. 2006; 17: 1111-1119.
48. Bottomley A, Coens C, Efficace F, et al., Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma?. A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. J Clin Oncol. 2007; 25: 5770-5776.
49. Bottomley A, Debruyne C, Felip E, et al., Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer. Eur J Cancer. 2008; 44: 2178-2184.
50. Bottomley A, Gaafar R, Gaafa R, et al., Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study. J Clin Oncol. 2006; 24: 1435-1442.
51. Bozcuk H, Dalmis B, Samur M, Ozdogan M, Artac M, Savas B,. Quality of life in patients with advanced non-small cell lung cancer. Cancer Nurs. 2006; 29: 104-110.
52. Brabo EP, Paschoal ME, Biasoli I, et al., Brazilian version of the QLQ-LC13 lung cancer module of the European Organization for Research and Treatment of Cancer: preliminary reliability and validity report. Qual Life Res. 2006; 15: 1519-1524.
53. Broberger E, Tishelman C, von Essen L, Doukkali E, Sprangers MA,. Spontaneous reports of most distressing concerns in patients with inoperable lung cancer: at present, in retrospect and in comparison with EORTC-QLQ-C30+LC13. Qual Life Res. 2007; 16: 1635-1645.
54. Brown J, Thorpe H, Napp V, et al., Assessment of quality of life in the supportive care setting of the big lung trial in non-small-cell lung cancer. J Clin Oncol. 2005; 23: 7417-7427.
55. Burfeind WR Jr, Jaik NP, Villamizar N, Toloza EM, Harpole DH Jr, D'Amico TA,. A cost-minimisation analysis of lobectomy: thoracoscopic versus posterolateral thoracotomy. Eur J Cardiothorac Surg. 2010; 37: 827-832.
56. Burt J, Plant H, Omar R, Raine R,. Equity of use of specialist palliative care by age: cross-sectional study of lung cancer patients. Palliat Med. 2010; 24: 641-650.
57. Cardenal F, Lõpez-Cabrerizo MP, Antõn A, et al., Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 1999; 17: 12-18.
58. Casal J, Amenedo M, Mel JR, et al., Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a Lung Cancer Galician Group phase II study. Cancer Chemother Pharmacol. 2007; 60: 725-732.
59. Chen M, Yu C, Yang C,. Sleep disturbances and quality of life in lung cancer patients undergoing chemotherapy. Lung Cancer. 2008; 62: 391-400.
60. Cheng X, Zhou D, Lv L,. Factors affecting the quality of life in lung cancer patients measured by EORTC QLQ questionnaire [article in Chinese]. Zhongguo Fei Ai Za Zhi. 2004; 7: 230-235.
61. Chie W, Yang C, Hsu C, Yang P,. Quality of life of lung cancer patients: validation of the Taiwan Chinese version of the EORTC QLQ-C30 and QLQ-LC13. Qual Life Res. 2004; 13: 257-262.
62. Coats V, Maltais F, Sinard S, et al., Feasibility and effectiveness of a home-based exercise training program before lung resection surgery [serial online]. Can Respir J. 2013; 20: e10-e16.
63. Cox K, Wilson E, Heath L, Collier J, Jones L, Johnston I,. Preferences for follow-up after treatment for lung cancer. Cancer Nurs. 2006; 29: 176-187.
64. Crinò L, Scagliotti GV, Ricci S, et al., Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol. 1999; 17: 3522-3530.
65. Cullen MH, Billingham LJ, Woodroffe CM, et al., Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol. 1999; 17: 3188-3194.
66. Dancey J, Shepherd FA, Gralla RJ, Kim YS,. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. Lung Cancer. 2004; 43: 183-194.
67. Danson S, Middleton MR, O'Byrne KJ, et al., Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer. 2003; 98: 542-553.
68. Debevec L, Rozman I,. Quality of life following thoracotomy for lung cancer. Radiol Oncol. 2007; 41: 144-151.
69. Di Maio M, Gridelli C, Gallo C, et al., Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer. Br J Cancer. 2004; 90: 2288-2296.
70. Di Maio M, Leighl NB, Gallo C, et al., Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer. J Thorac Oncol. 2012; 7: 1830-1844.
71. Efficace F, Bottomley A, Smit EF, et al,. Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients?. A multivariate analysis of prognostic factors of EORTC study 08975. Ann Oncol. 2006; 17: 1698-1704.
72. Fløtten Ø, Grønberg BH, Bremnes R, et al., Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group. Br J Cancer. 2012; 107: 442-447.
73. Franceschini J, Jardim JR, Fernandes AL, Jamnik S, Santoro IL,. Reproducibility of the Brazilian Portuguese version of the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire used in conjunction with its lung cancer-specific module [article in English, Portuguese]. J Bras Pneumol. 2010; 36: 595-602.
74. Garassino MC, Martelli O, Broggini M, et al., Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol. 2013; 14: 981-988.
75. Gebbia V, Galetta D, Lorusso V, et al., Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the GOIM (Gruppo Oncologico Italia Meridionale). Lung Cancer. 2008; 61: 369-377.
76. Gebbia V, Lorusso V, Galetta D, et al., First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale. Lung Cancer. 2010; 69: 218-224.
77. Gebbia V, Gridelli C, Verusio C, et al., Weekly docetaxel vs docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients: the DISTAL-2 randomized trial. Lung Cancer. 2009; 63: 251-258.
78. Gelibter A, Ceribelli A, Pollera CF, et al., Impact of gefitinib ("Iressa") treatment on the quality of life of patients with advanced non-small-cell lung cancer. J Cancer Res Clin Oncol. 2005; 131: 783-788.
79. Giaccone G, Splinter TA, Debruyne C, et al., Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol. 1998; 16: 2133-2141.
80. Gomez Aparicio M, Iglesias A, Martinez E, Escolar P, Salinas J,. Initial outcomes in lung cancer treatment with VMAT [abstract]. Rep Practical Oncol Radiother. 2013; 18 (suppl 1): S264.
81. Gore M, Brophy CJ, Greenstone MA,. How well do we care for patients with end stage chronic obstructive pulmonary disease (COPD)?. A comparison of palliative care and quality of life in COPD and lung cancer. Thorax. 2000; 55: 1000-1006.
82. Goss GD, Arnold A, Shepherd FA, et al., Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC Clinical Trials Group BR24 study. J Clin Oncol. 2009; 28: 49-55.
83. Granger CL, Chao C, McDonald CF, Berney S, Denehy L,. Safety and feasibility of an exercise intervention for patients following lung resection: a pilot randomized controlled trial. Integr Cancer Ther. 2013; 12: 213-224.
84. Gridelli C, Frontini L, Perrone F, et al., Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of 3 different doses. Br J Cancer. 2000; 83: 707-714.
85. Gridelli C, Gallo C, Di Maio M, et al., A randomised clinical trial of 2 docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer. 2004; 91: 1996-2004.
86. Gridelli C, Perrone F, Gallo C, et al., Single-agent gemcitabine as second-line treatment in patients with advanced nonsmall cell lung cancer (NSCLC): a phase II trial. Anticancer Res. 2999; 19 (5C): 4535-4538.
87. Gridelli C, Gallo C, Ceribelli A, et al., Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. Lancet Oncol. 2007; 8: 500-512.
88. Gridelli C, Gallo C, Morabito A, et al., Phase I-II trial of gemcitabine-based first-line chemotherapies for small cell lung cancer in elderly patients with performance status 0-2: the G-Step trial. J Thorac Oncol. 2012; 7: 233-242.
89. Gridelli C, Gallo C, Shepherd FA, et al., Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003; 21: 3025-3034.
90. Gridelli C, Perrone F, Gallo C, et al., Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst. 2003; 95: 362-372.
91. Groen HJ, van der Lees AH, Fokkema E, et al., Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study. Ann Oncol. 2004; 15: 427-432.
92. Grønberg BH, Bremnes RM, Flotten O, et al., Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2009; 27: 3217-3224.
93. Grønberg BH, Sundstrøm S, Kaasa S, et al., Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy. Eur J Cancer. 2010; 46: 2225-2234.
94. Habraken JM, ter Riet G, Gore JM, et al., Health-related quality of life in end-stage COPD and lung cancer patients. J Pain Symptom Manage. 2009; 37: 973-981.
95. Hallqvist A, Wagenius G, Rylander H, et al., Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite-a phase II study from the Swedish Lung Cancer Study Group. Lung Cancer. 2011; 71: 166-172.
96. Hallqvist A, Bergman B, Nyman J,. Health related quality of life in locally advanced NSCLC treated with high dose radiotherapy and concurrent chemotherapy or cetuximab-pooled results from 2 prospective clinical trials. Radiother Oncol. 2012; 104: 39-44.
97. Han JY, Park K, Kim SW, et al., First-SIGNAL: first-line single-agent Iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 2012; 10: 1122-1128.
98. Haskell CM, Mendoza E, Pisters KM, Fossella FV, Figlin RA,. Phase II study of intravenous adenosine 5′-triphosphate in patients with previously untreated stage IIIB and stage IV non-small cell lung cancer. Invest New Drugs. 1998; 16: 81-85.
99. Hatton M, Nankivell M, Lyn E, et al., Induction chemotherapy and continuous hyperfractionated accelerated radiotherapy (chart) for patients with locally advanced inoperable non-small-cell lung cancer: the MRC INCH randomized trial. Int J Radiat Oncol Biol Phys. 2011; 81: 712-718.
100. Helbekkmo N, Sundstrøm SH, Aasebø U, et al., Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer. 2007; 97: 283-289.
101. Helbekkmo N, Aasebø U, Sundstrøm SH, et al., Treatment outcome in performance status 2 advanced NSCLC patients administered platinum-based combination chemotherapy. Lung Cancer. 2008; 62: 253-260.
102. Helbekkmo N, Strøm HH, Sundstrøm SH, Aasebø U, Von Plessen C, Bremnes RM,. Chemotherapy and quality of life in NSCLC PS 2 patients. Acta Oncol. 2009; 48: 1019-1025.
103. Helsing M, Bergman B, Thaning L, Hero U,. Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. Joint Lung Cancer Study Group. Eur J Cancer. 1998; 34: 1036-1044.
104. Henke CC, Cabri J, Fricke L, et al., Strength and endurance training in the treatment of lung cancer patients in stages IIIA/IIIB/IV. Support Care Cancer. 2014; 22: 95-101.
105. Henke C, Cabri J, Fricke L, Kandilakis G, Wulf P, Feyer PC, De Wit M,. Enhanced physical activity intervention in lung cancer patients during palliative chemotherapy-a randomized controlled trial [abstract]. Onkologie. 2012; 35 (suppl 6): 139. Abstract P473.
106. Henoch I, Bergman B, Gaston-Johansson F,. Validation of a Swedish version of the Cancer Dyspnea Scale. J Pain Symptom Manage. 2006; 31: 353-361.
107. Henoch I, Ploner A, Tishelman C,. Increasing stringency in symptom cluster research: a methodological exploration of symptom clusters in patients with inoperable lung cancer [serial online]. Oncol Nurs Forum. 2009; 36: E282-E292.
108. Hermes A, Bergman B, Bremnes R, et al., Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol. 2008; 26: 4261-4267.
109. Herndon JE 2nd, Fleishman S, Kornblith AB, Kosty M, Grenn MR, Holland J,. Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma? Cancer. 1999; 85: 333-340.
110. Herndon JE, Fleishman S, Kosty MP, Green MR,. A longitudinal study of quality of life in advanced non-small cell lung cancer: Cancer and Leukemia Group B (CALGB) 8931. Control Clin Trials. 1997; 18: 286-300.
111. Hickish TF, Smith IE, Nicolson MC, et al., A pilot study of MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in small-cell lung cancer. Br J Cancer. 1998; 77: 1966-1970.
112. Hilarius DL, Kloeg PH, Gundy CM, Aaronson NK,. Use of health-related quality-of-life assessments in daily clinical oncology nursing practice. Cancer. 2008; 113: 628-637.
113. Hirsh V, Cadranel J, Cong XJ, et al., Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1). J Clin Oncol. 2013; 8: 229-237.
114. Jain S, Poon I, Soliman H, et al., Lung stereotactic body radiation therapy (SBRT) delivered over 4 or 11 days: a comparison of acute toxicity and quality of life. Radiother Oncol. 2013; 108: 320-325.
115. Jassem J, Krazakowski M, Roszkowski K, et al., A phase II study of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer: clinical outcomes and quality of life. Lung Cancer. 2002; 35: 73-79.
116. Karbasi Motlagh M, Enjedani E, Zamanian H, et al., Validity and reliability of lung cancer quality of life questionnaire from European Organization for Research and Treatment of Cancer (EORTC QLQ-LC13) in Iran. HealthMED. 2012; 6: 2121-2124.
117. Kenny PM, King MT, Viney RC, et al., Quality of life and survival in the 2 years after surgery for non-small-cell lung cancer. J Clin Oncol. 2008; 26: 233-241.
118. Kim DW, Blackhall F, Soria JC, et al., A global phase 2 study including efficacy, safety and patient-reported outcomes (PROs) with crizotinib in patients (Pts) with ALK-positive non-small cell lung cancer (NSCLC). Eur J Cancer. 2011; 47: S617-S617.
119. Kivrak-Bernardelli BG, Çaʇlar M, Kadiʇlu SB, Salepci T, Clark PM,. Quality of life assessment of patients with metastatic lung cancer receiving plantinum-based chemotherapy. Marmara Pharm J. 2013; 2: 120-130.
120. Kobayashi K, Nomura K, Wakasawa S, et al., Quality of life (QOL) and nutrition [article in Japanese]. Gan To Kagaku Ryoho. 1991; 18: 1031-1038.
121. Kosty MP, Fleishman SB, Herndon JE II, et al., Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B. J Clin Oncol. 1994; 12: 1113-1120.
122. Kumbhaj P, Sharma R, Singh DP, Sharma OP, Bhatnagar AR,. Comparative study of 2 hypofractionated palliative radiotherapy regimens in locally advanced non-small cell lung carcinoma [abstract]. J Thorac Oncol. 2012; 7: 174.
123. Laack E, Dickgreber N, Müller T, et al., Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group. J Clin Oncol. 2004; 22: 2348-2356.
124. Langendijk H, de Jong J, Tjwa M, et al., External irradiation versus external irradiation plus endobronchial brachytherapy in inoperable non-small cell lung cancer: a prospective randomized study. Radiother Oncol. 2001; 58: 257-268.
125. Langendijk JA, Aaronson NK, de Jong JM, et al., Prospective study on quality of life before and after radical radiotherapy in non-small-cell lung cancer. J Clin Oncol. 2001; 19: 2123-2133.
126. Langendijk JA, ten Velde GP, Aaronson NK, de Jong JM, Muller MJ, Wouters EF,. Quality of life after palliative radiotherapy in non-small cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys. 2000; 47: 149-155.
127. Langendijk JA, Aaronson NJ, de Jong JM, et al., Quality of life after curative radiotherapy in stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002; 53: 847-853.
128. Langendijk JA, Aaronson NK, ten Velde GP, et al., Pretreatment quality of life of inoperable non-small cell lung cancer patients referred for primary radiotherapy. Acta Oncol. 2000; 39: 949-958.
129. Larsson M, Ljung L, Johansson BB,. Health-related quality of life in advanced nonsmall cell lung cancer: correlates and comparisons to normative data. Eur J Cancer Care (Engl). 2012; 2: 642-649.
130. LeCaer H, Delhoume JY, Thomas PA, et al., Multicenter phase II trial of carboplatin/vinorelbine in elderly patients with advanced non-small-cell lung cancer efficacy and impact on quality of life: Groupe Francais de Pneumo-Cancerologie Study 9902. Clin Lung Cancer. 2005; 7: 114-120.
131. Lee DH, Han JY, Kim HT, et al., Primary chemotherapy for newly diagnosed non-small cell lung cancer patients with synchronous brain metastases compared with whole-brain radiotherapy administered first: Result of a randomized pilot study. Cancer. 2008; 113: 143-149.
132. Lee DH, Han J, Yu SU, et al., The role of gefitinib treatment for Korean never-smokers with advanced or metastatic adenocarcinoma of the lung: a prospective study. J Thorac Oncol. 2006; 1: 965-971.
133. Lee SM, James LE, Qian W, et al., Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer. Thorax. 2009; 64: 75-80.
134. Lee SM, Rudd R, Woll PJ, et al., Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2009; 27: 5248-5254.
135. Leighl NB, Paz-Ares L, Douillard JY, et al., Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. J Clin Oncol. 2004; 23: 2831-2839.
136. Leo F, Radice D, Didier F, et al., Does a personalized approach improve patient satisfaction in thoracic oncology? Am J Manag Care. 2009; 15: 361-367.
137. Leo F, Scanagatta P, Vannucci F, Brambilla D, Radice D, Spaggiari L,. Impaired quality of life after pneumonectomy: who is at risk? J Thorac Cardiovasc Surg. 2010; 139: 49-52.
138. Leong SS, Toh CK, Lim WT, et al., A randomized phase II trial of single-agent gemcitabine, vinorelbine, or docetaxel in patients with advanced non-small cell lung cancer who have poor performance status and/or are elderly. J Thorac Oncol. 2007; 2: 230-236.
139. Leppert W, Turska A, Majkowicz M, Dziegielewska S, Pankiewicz P, Mess E,. Quality of life in patients with advanced lung cancer treated at home and at a palliative care unit. Am J Hosp Palliat Med. 2012; 29: 379-387.
140. Lheureux M, Raherison C, Vernejoux JM, et al., Quality of life in lung cancer: does disclosure of the diagnosis have an impact? Lung Cancer. 2004; 43: 175-182.
141. Li TC, Li CI, Tseng CH, et al., Quality of life predicts survival in patients with non-small cell lung cancer [serial online]. BMC Public Health. 2012; 12: 790.
142. Zhang XT, Li LY, Wang SL, Mu XL, Wang MS, Song W,. Improvements in quality of life and disease-related symptoms in patients with advanced non-small cell lung cancer treated with gefitinib. Chin Med J (Engl). 2005; 118: 1661-1664.
143. Li Y, Zhou X, Zhang T, Chen H,. Attenuating effect of Shenqifuzheng injection on toxic reactions of NP chemotherapy in patients with non-small cell lung cancer. Chin J New Drugs. 2010; 2: 123-126. Available at: http://en.cnki.com.cn/Article-en/CJFDTOTAL-ZXYZ201002013.htm. Accessed April 27, 2014.
144. Li WW, Lee TW, Lam SS, et al., Quality of life following lung cancer resection: video-assisted thoracic surgery vs thoracotomy. Chest. 2002; 122: 584-589.
145. Lilenbaum R, Axelrod R, Thomas S, et al., Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J Clin Oncol. 2008; 26: 863-869.
146. Lovgren M, Tishelman C, Sprangers M, Koyi H, Hamberg K,. Symptoms and problems with functioning among women and men with inoperable lung cancer-a longitudinal study. Lung Cancer. 2008; 60: 113-124.
147. Mallick I, Sharma SC, Behera D, Ghoshal S, Oinam AS,. Optimization of dose and fractionation of endobronchial brachytherapy with or without external radiation in the palliative management of non-small cell lung cancer: a prospective randomized study. J Cancer Res Ther. 2006; 2: 119-125.
148. Mallick I, Sharma SC, Behera D,. Endobronchial brachytherapy for symptom palliation in non-small cell lung cancer-analysis of symptom response, endoscopic improvement and quality of life. Lung Cancer. 2007; 55: 313-318.
149. Manegold C, Pilz LR, Koschel G, et al., Randomized multicenter phase II study of gemcitabine versus docetaxel as first-line therapy with second-line crossover in advanced-stage non-small-cell lung cancer. Clin Lung Cancer. 2005; 7: 208-214.
150. Manegold C, Koschel G, Hruska D, Scott-von-Römer K, Mezger J, Pilz LR,. Open, randomized, phase II study of single-agent gemcitabine and docetaxel as first- and second-line treatment in patients with advanced non-small-cell lung cancer. Clin Lung Cancer. 2007; 8: 245-251.
151. Maric D, Jovanovic D, Golubicic I, Dimic S, Pekmezovic T,. Health-related quality of life in lung cancer patients in Serbia: correlation with socio-economic and clinical parameters. Eur J Cancer Care (Engl). 2010; 19: 594-602.
152. Miller VA, Hirsh V, Cadranel J, et al., Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and 1 or 2 lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 2012; 13: 528-538.
153. Mills ME, Murray LJ, Johnston BT, Cardwell C, Donnelly M,. Does a patient-held quality-of-life diary benefit patients with inoperable lung cancer? J Clin Oncol. 2009; 27: 70-77.
154. Mills ME, Murray LJ, Johnston BT, Donnelly M,. Feasibility of a standardised quality of life questionnaire in a weekly diary format for inoperable lung cancer patients. Eur J Oncol Nurs. 2008; 12: 457-463.
155. Mohamed IG, Docherty CF, Germain F, Hoegler D, Petrik D, Halperin R,. The influence of social and geographic isolation on depressive symptoms in patients with lung cancer receiving radiotherapy (RT) [abstract]. J Thorac Oncol. 2012; 7: 333.
156. Mohan A, Singh P, Singh S, et al., Quality of life in lung cancer patients: impact of baseline clinical profile and respiratory status. Eur J Cancer Care (Engl). 2007; 16: 268-276.
157. Mok TS, Lam KC, Lee C, et al., Phase II randomized study comparing the toxicity profile of gemcitabine plus cisplatin with gemcitabine plus oral etoposide in the treatment of advanced non-small cell lung cancer. Oncology. 2005; 68: 485-492.
158. Mok T, Kris MG, Ou SH, et al., Efficacy, safety, and patient-reported outcomes of first-line dacomitinib (PF-00299804), an irreversible pan-her tyrosine kinase inhibitor, in patients with lung cancers harboring EGFR exon 21 mutation or EGFR exon 19 deletion [abstract]. J Thorac Oncol. 2012; 7: 453.
159. Montazeri A, Milroy R, Gillis CR, Mc Ewen J,. Interviewing cancer patients in a research setting: the role of effective communication. Support Care Cancer. 1996; 4: 447-454.
160. Montazeri A, Hole DJ, Milroy R, McEwen J, Gillis CR,. Quality of life in lung cancer patients: does socioeconomic status matter [serial online]? Health Qual Life Outcomes. 2003; 1: 19.
161. Montazeri A, Hole DJ, Milroy R, McEwen J, Gillis CR,. Does knowledge of cancer diagnosis affect quality of life?. A methodological challenge [serial online]. BMC Cancer. 2004; 4: 21.
162. Montazeri A, Milroy R, Hole DJ, Gillis CR, Mc Ewen J,. Quality of life in lung cancer patients as an important prognostic factor. Lung Cancer. 2001; 31: 233-240.
163. Montazeri A, Milroy R, Hole DJ, McEwen J, Gillis CR,. How quality of life data contribute to our understanding of cancer patients' experiences?. A study of patients with lung cancer. Qual Life Res. 2003; 12: 157-166.
164. Movsas B, Scott C, Langer C, et al., Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: Radiation Therapy Oncology Group trial 98-01. J Clin Oncol. 2005; 23: 2145-2154.
165. Movsas B, Moughan J, Sarna L, et al., Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. J Clin Oncol. 2009; 27: 5816-5822.
166. Mu X, Li L, Zhang X, Wang S, Wang M,. The role of epidermal growth factor receptor inhibitor, gefitinib, in improvement of quality of life of patients with non-small cell lung cancer [article in Chinese]. Zhongguo Fei Ai Za Zhi. 2005; 8: 313-316.
167. Mu X, Li L, Zhang X, Wang S, Wang M,. Evaluation of safety and efficacy of gefitinib ("Iressa," zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use program [serial online]. BMC Cancer. 2004; 4: 51.
168. Muers MF, Rudd RM, O'Brien ME, et al., BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112. Thorax. 2004; 59: 144-148.
169. Muers MF, Stephens RJ, Fisher P, et al., Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet. 2008; 371: 1685-1694.
170. Natale RB, Thongprasert S, Greco FA, et al., Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2011; 8: 1059-1066.
171. Nelson JE, Gay EB, Berman AR, Powell CA, Salazar-Schicchi J, Wisnivesky JP,. Patients rate physician communication about lung cancer. Cancer. 2011; 117: 5212-5220.
172. Neumann K, Sundset A, Espinoza A, Kongerud J, Fosse E,. Changes in quality of life, dyspnea scores, and lung function in lung cancer patients with airway obstruction after a therapeutic bronchoscopy. J Bronchology Interv Pulmonol. 2013; 20: 134-139.
173. Nguyen J, Chu D, Bedard G, et al., Palliative radiotherapy in the treatment of lung metastases or advanced lung cancer. J Pain Manage. 2013; 6: 77-82.
174. Nicklasson M, Bergman B,. Validity, reliability and clinical relevance of EORTC QLQ-C30 and LC13 in patients with chest malignancies in a palliative setting. Qual Life Res. 2007; 16: 1019-1028.
175. Nicklasson M, Elfström ML, Olofson J, Bergman B,. The impact of individual quality of life assessment on psychosocial attention in patients with chest malignancies: a randomized study. Support Care Cancer. 2013; 21: 87-95.
176. Nowak AK,. Assessing quality of life during chemotherapy for pleural mesothelioma: feasibility, validity, and results of using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire and Lung Cancer Module. J Clin Oncol. 2004; 22: 3172-3180.
177. Nyman J, Friesland S, Hallqvist A, et al., How to improve loco-regional control in stages IIIa-b NSCLC?. Results of a 3-armed randomized trial from the Swedish Lung Cancer Study Group. Lung Cancer. 2009; 65: 62-67.
178. O'Brien ME, Anderson H, Kaukel E, et al., SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality in patients with advanced non-small-cell lung cancer: phase III results. Ann Oncol. 2004; 15: 906-914.
179. Oliveira PI, Pereira CA, Belasco AG, Bettencourt AR,. Comparison of the quality of life among persons with lung cancer, before and after the chemotherapy treatment [article in English, Portuguese, Spanish]. Rev Lat Am Enfermagem. 2013; 21: 787-794.
180. Östlund U, Wennman-Larsen A, Gustavsson P, Wengström Y,. What symptom and functional dimensions can be predictors for global ratings of overall quality of life in lung cancer patients? Support Care Cancer. 2007; 15: 1199-1205.
181. Oviatt PL, David R. Stather, Michaud G, MacEachern P, Tremblay A,. Exercise capacity, lung function, and quality of life after interventional bronchoscopy. J Thorac Oncol. 2011; 6: 38-42.
182. Paccagnella A, Favaretto A, Oniga F, et al., Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non-small cell lung cancer. A multicenter, randomized phase III trial. Lung Cancer. 2004; 43: 83-91.
183. Park JO, Kim S, Ahn JS, et al., Phase III trial of 2 versus 4 additional cycles in patients who are nonprogressive after 2 cycles of platinum-based chemotherapy in non-small-cell lung cancer. J Clin Oncol. 2007; 25: 5233-5239.
184. Park S, Kim IR, Baek KK, et al., Prospective analysis of quality of life in elderly patients treated with adjuvant chemotherapy for non-small-cell lung cancer. Ann Oncol. 2013; 24: 1630-1639.
185. Perez-Soler R,. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 2004; 22: 3238-3247.
186. Peters A,. Lebensqualität und Akuttoxizität im Rahmen einer Radiotherapie unter Berücksichtigung von Alter, Behandlungsregion und anderen Faktoren [dissertation]. Düsseldorf, Germany: Heinrich-Heine-Universität; 2002.
187. Pijls-Johannesma M, Houben R, Boersma L, et al., High-dose radiotherapy or concurrent chemo-radiation in lung cancer patients only induces a temporary, reversible decline in QoL. Radiother Oncol. 2009; 91: 443-448.
188. Pirker R, Pereira JR, Szczesna A, et al., Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009; 373: 1525-1531.
189. von Plessen C, Bergman B, Andresen O, et al., Palliative chemotherapy beyond 3 courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer. 2006; 95: 966-973.
190. Pompili C, Brunelli A, Xiumé F, et al., Prospective external convergence evaluation of 2 different quality-of-life instruments in lung resection patients. Eur J Cardiothorac Surg. 2011; 40: 99-105.
191. Pujol JL, Breton J, Gervais R, et al., Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol. 2005; 16: 602-610.
192. Putten JW, Baas P, Codrington H, et al., Activity of single-agent gemcitabine as second-line treatment after previous chemotherapy or radiotherapy in advanced non-small-cell lung cancer. Lung Cancer. 2001; 33: 289-298.
193. Quantin XM, Rivière AM, Daurès JM, et al., Phase I-II study of high dose epirubicin plus cisplatin in unresectable non-small-cell lung cancer: searching for the maximal tolerated dose. Am J Clin Oncol. 2000; 23: 192-196.
194. Ramalingam SS, Blackhall F, Krzakowski M, et al., Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2012; 30: 3337-3344.
195. Reck M, Kaiser R, Eschbach C, et al., A phase II double-blind study to investigate efficacy and safety of 2 doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann Oncol. 2011; 22: 1374-1381.
196. Riesenberg H, Lübbe AS,. In-patient rehabilitation of lung cancer patients-a prospective study. Support Care Cancer. 2010; 18: 877-882.
197. Rosell R, Gatzemeier U, Betticher DC, et al., Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol. 2002; 13: 1539-1549.
198. Rudd RM, Gower NH, Spiro SG, et al., Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J Clin Oncol. 2005; 23: 142-153.
199. Rumble ME, Keefe FJ, Edinger JD, Porter LS, Garst JL,. A pilot study investigating the utility of the cognitive-behavioral model of insomnia in early-stage lung cancer patients. J Pain Symptom Manage. 2005; 30: 160-169.
200. Sabur NF, Chee A, Stather DR, et al., The impact of tunneled pleural catheters on the quality of life of patients with malignant pleural effusions. Respiration. 2013; 85: 36-42.
201. Sánchez-Lara K, Turcott JG, Juárez E, et al., Association of nutrition parameters including bioelectrical impedance and systemic inflammatory response with quality of life and prognosis in patients with advanced non-small-cell lung cancer: a prospective study. Nutr Cancer. 2012; 64: 526-534.
202. Sarna L, Swann S, Langer C, et al., Clinically meaningful differences in patient-reported outcomes with amifostine in combination with chemoradiation for locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. Int J Radiat Oncol Biol Phys. 2008; 72: 1378-1384.
203. Scagliotti GV, Marinis FD, Rinaldi M, et al., Phase III randomized trial comparing 3 platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol. 2002; 20: 4285-4291.
204. Schulte T, Schniewind B, Dohrmann P, Küchler T, Kurdow R,. The extent of lung parenchyma resection significantly impacts long-term quality of life in patients with non-small cell lung cancer. Chest. 2009; 135: 322-329.
205. Schulte T, Schniewind B, Walter J, Dohrmann P, Küchler T, Kurdow R,. Age-related impairment of quality of life after lung resection for non-small cell lung cancer. Lung Cancer. 2010; 68: 115-120.
206. Schumacher A, Riesenbeck D, Braunheim M, et al., Combined modality treatment for locally advanced non-small cell lung cancer: preoperative chemoradiation does not result in a poorer quality of life. Lung Cancer. 2004; 44: 89-97.
207. Sederholm C, Hillerdal G, Lamberg K, et al., Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol. 2005; 23: 8380-8388.
208. Shan MJ, Han BH, You J,. Assessment of therapeutic efficacy on treating advanced non-small cell lung cancer in the aged by Chinese medicine adopting the international questionnaire of quality of life [article in Chinese]. Zhonggou Zhong Xi Yi Jie He Za Zhi. 2011; 31: 873-879.
209. Shaw AT, Kim DW, Nakagawa K, et al., Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013; 25: 2385-2394.
210. Shepherd FA, Dancey J, Ramlau R, et al., Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000; 18: 2095-2103.
211. Shepherd FA, Rodrigues Peira J, Ciuleanu T, et al., Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353: 123-132.
212. Smit EF, van Meerbeeck JP, Lianes P, et al., Three-arm randomized study of 2 cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol. 2003; 21: 3909-3917.
213. Smith IE, O'Brien ME, Talbot DC, et al., Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of 3 versus 6 courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol. 2001; 19: 1336-1343.
214. Socci L, Raffle D, Barua A, Parmar V, Kumaran M, Martin-Ucar AE,. Preserving the lung during radical surgery for mesothelioma: quality of life, spirometry and lung volume measurements. Lung Cancer. 2012; 75 (suppl 1): S22-S23.
215. Sørensen JB, Bergman B, Nielsen AL, Krarup M, Dombernowsky P, Hansen HH,. Phase II study of gemcitabine and vindesine in patients with previously untreated nonresectable non-small-cell lung cancer. Br J Cancer. 1999; 79: 875-881.
216. Spiro SG, Rudd RM, Souhami RL, et al., Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax. 2004; 59: 828-836.
217. Sterzi S, Cesario A, Cusumano G, et al., How best to assess the quality of life in long-term survivors after surgery for NSCLC?. Comparison between clinical predictors and questionnaire scores. Clin Lung Cancer. 2013; 14: 78-87.
218. Sundstrøm S, Bremnes R, Aasebø U, et al., Hypofractionated palliative radiotherapy (17 Gy per 2 fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial. J Clin Oncol. 2004; 22: 801-810.
219. Sundstrøm S, Bremnes RM, Brunsvig P, et al., Immediate or delayed radiotherapy in advanced non-small cell lung cancer (NSCLC)?. Data from a prospective randomised study. Radiother Oncol. 2005; 75: 141-148.
220. Sundstrøm S, Bremnes RM, Brunsvig P, Aasebø U, Kaasa S,; Norwegian Lung Cancer Study Group. Palliative thoracic radiotherapy in locally advanced non-small cell lung cancer: can quality-of-life assessments help in selection of patients for short- or long-course radiotherapy? J Thorac Oncol. 2006; 1: 816-824.
221. Sundstrøm S, Bremnes RM, Kaasa S, et al., Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol. 2002; 20: 4665-4672.
222. Suzuki R, Yamamoto M, Saka H, et al., A phase II study of carboplatin and paclitaxel with meloxicam. Lung Cancer. 2009; 63: 72-76.
223. ten Bokkel Huinink WW, Bergman B, Chemaissani A, et al., Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer. Lung Cancer. 1999; 26: 85-94.
224. Thatcher N, Qian W, Clark PI, et al., Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: clinical and quality-of-life results of the British Medical Research Council multicenter randomized LU21 trial. J Clin Oncol. 2005; 23: 8371-8379.
225. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst. 1999; 91: 66-72.
226. Tishelman C, Lovgren M, Broberger E, Hamberg K, Sprangers MA,. Are the most distressing concerns of patients with inoperable lung cancer adequately assessed?. A mixed-methods analysis. J Clin Oncol. 2010; 28: 1942-1949.
227. Tishelman C, Petersson L, Degner LF, Sprangers MA,. Symptom prevalence, intensity, and distress in patients with inoperable lung cancer in relation to time of death. J Clin Oncol. 2007; 25: 5381-5389.
228. Trafalis DT, Alifieris C, Krikelis D, et al., Topotecan and pegylated liposomal doxorubicin combination as palliative treatment in patients with pretreated advanced malignant pleural mesothelioma. Int J Clin Pharmacol Ther. 2012; 50: 490-499.
229. Turner NJ, Muers MF, Haward RA, Mulley GP,. Do elderly people with lung cancer benefit from palliative radiotherapy? Lung Cancer. 2005; 49: 193-202.
230. van der Voort van Zyp NC, Prévost JB, van der Holt B, et al., Quality of life after stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2010; 77: 31-37.
231. van Haarst JM, van Klaveren RJ, Baas P, et al., Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer. 2002; 86: 342-345.
232. van Meerbeeck JP, Gaafar R, Manegold C, et al., Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 2005; 23: 6881-6889.
233. Vandenbos F, Fontas É, Dunais B, et al., Pulmonary rehabilitation after lung resection for tumor-a feasibility study [article in French]. Rev Mal Respir. 2013; 30: 56-61.
234. Vilmar A, Santoni-Rugiu E, Sørensen JB,. ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial. Eur J Cancer. 2010; 46: 1554-1562.
235. Vilmar AC, Santoni-Rugiu E, Sorensen JB,. Class III β-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial. Clin Cancer Res. 2011; 17: 5205-5214.
236. Visser MR, van Lanschot JJ, van der Velden J, Kloek JJ, Gouma DJ, Sprangers MA,. Quality of life in newly diagnosed cancer patients waiting for surgery is seriously impaired. J Surg Oncol. 2006; 93: 571-577.
237. Vos MS, Putter H, van Houwelingen HC, de Haes HC,. Denial and physical outcomes in lung cancer patients, a longitudinal study. Lung Cancer. 2010; 67: 237-243.
238. Wachowicz M, Furmanik F,. Quality of life assessment in patients with non-small cell lung cancer treated surgically or with pre-operative chemotherapy followed by surgery [article in Polish]. Pneumonol Alergol Pol. 2003; 71: 121-131.
239. Wachters FM, van Putten JW, Kramer H, et al., First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial. Br J Cancer. 2003; 89: 1192-1199.
240. Wachters FM, Van Der Graaf WT, Groen HJ,. Cardiotoxicity in advanced non-small cell lung cancer patients treated with platinum and non-platinum based combinations as first-line treatment. Anticancer Res. 2004; 24 (3b): 2079-2083.
241. Wan C, Zhang C, Tu X, et al., Validation of the simplified Chinese version of the quality of life instrument EORTC QLQ-LC43 for patients with lung cancer. Cancer Invest. 2008; 26: 504-510.
242. Wang JP, Lin W, Cui J,. Quality of life and its related factors in lung or breast cancer patients. Chin J Clin Psychol. 2002; 10: 176-178.
243. Welter S, Schwan A, Cheufou D, et al., Midterm changes in quality of life: a prospective evaluation after open pulmonary metastasectomy. Ann Thorac Surg. 2013; 95: 1006-1011.
244. Wennman-Larsen A, Tishelman C, Wengström Y, Gustavsson P,. Factors influencing agreement in symptom ratings by lung cancer patients and their significant others. J Pain Symptom Manage. 2007; 33: 146-155.
245. Wheatley-Price P, Le Maître A, Ding K, et al., The influence of sex on efficacy, adverse events, quality of life, and delivery of treatment in National Cancer Institute of Canada Clinical Trials Group non-small cell lung cancer chemotherapy trials. J Thorac Oncol. 2010; 5: 640-648.
246. Widder J, Bantema-Joppe E, Ubbels F, Wiegman E, Langendijk J,. Health-related quality of life and pulmonary symptoms after SBRT for early lung cancer and lung metastases. Radiother Oncology. 2010; 108: 320-325.
247. Widder J, Postmus D, Ubbels JF, Wiegman EM, Langendijk JA,. Survival and quality of life after stereotactic or 3D-conformal radiotherapy for inoperable early-stage lung cancer [serial online]. Int J Radiat Oncol Biol Phys. 2011; 81: e291-e297.
248. Win T, Sharples L, Wells FC, Ritchie AJ, Munday H, Laroche CM,. Effect of lung cancer surgery on quality of life. Thorax. 2005; 60: 234-238.
249. Xará S, Amaral TF, Parente B,. Undernutrition and quality of life in nonsmall cell lung cancer patients [article in Portuguese]. Rev Port Pneumol. 2011; 17: 153-158.
250. Yang JC, Hirsh V, Schuler M, et al., Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013; 31: 3342-3350.
251. Yun YH, Kim SH, Lee KM, Park SM, Kim YM,. Age, sex, and comorbidities were considered in comparing reference data for health-related quality of life in the general and cancer populations. J Clin Epidemiol. 2007; 60: 1164-1175.
252. Yun YH, Kim YA, Min YH, et al., Health-related quality of life in disease-free survivors of surgically treated lung cancer compared with the general population. Ann Surg. 2012; 255: 1000-1007.
253. Zhang T,. Effect of TCM therapy for removing toxic substance and unblocking meridians on post-radiation quality of life in 55 patients with lung cancer [article in Chinese]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2008; 28: 154-157.
254. Zhang T, Ma SL, Yue JH,. Clinical study on toxicity-attenuation effect of Yiguan Decoction in treatment of non-small cell lung cancer with NP protocol of chemotherapy [article in Chinese]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2007; 27: 396-399.
255. Zhang X, Li L, Mu X, Wang S,. ZD1839 (Iressa) in the treatment of non-small cell lung cancer patients [article in Chinese]. Zhongguo Fei Ai Za Zhi. 2004; 7: 309-312.
256. Zhou SW, Ren SX, Yan LH, Zhang L, Zhou CC,. Impact of erlotinib treatment on symptoms and quality of life in patients with advanced non-small-cell lung cancer [article in Chinese]. Zhonghua Zhong Liu Za Zhi. 2008; 30: 469-472.
257. Zou Y, Xiong H, Yu S,. Improvements of quality of life in patients with advanced non-small cell lung cancer treated with gefitinib. Chin German J Clin Oncol. 2009; 8: 495-497.
258. Zumtobel M, End A, Bigenzahn W, Klepetko W, Schneider B,. Reduced quality of life in patients with unilateral vocal cord paralysis after thoracic surgery [article in German]. Chirurg. 2006; 77: 518-522.
259. Kuliš D, Arnott M, Greimel ER, Bottomley A, Koller M,; European Organisation for Research and Treatment of Cancer Quality of Life Group. Trends in translation requests and arising issues regarding cultural adaptation. Expert Rev Pharmacoecon Outcomes Res. 2011; 11: 307-314.
260. Zikos E, Ghislain I, Coens C, et al., Health-related quality of life in small-cell lung cancer: a systematic review on reporting of methods and clinical issues in randomised controlled trials [serial online]. Lancet Oncol. 2014; 15: e78.
261. Singer S, Arraras JI, Chie W, et al., Performance of the EORTC questionnaire for the assessment of quality of life in head and neck cancer patients EORTC QLQ-H&N35: a methodological review. Qual Life Res. 2013; 22: 1927-1941.
262. Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD,. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013; 309: 814-822.
263. Chu D, Nguyen J, Koo K, et al., An update on the quality of life measurements in lung cancer patients receiving palliative radiotherapy: a literature review. World J Oncol. 2013; 4: 67-73.